← News
Aug 12, 2026 Psychedelics
MindMed Renamed Itself Definium — And Its LSD Trial Just Posted Positive Phase 3 Results
MindMed renamed itself Definium Therapeutics, Inc. (NASDAQ: DFTX) in January, and its LSD compound went from MM120 to DT120 in the same move. This week, the company reported positive Phase 3 results from Voyage, its lead trial for generalized anxiety disorder — meeting the primary endpoint with a strong effect size. A second GAD trial and an already-positive depression trial are also underway. Right now, this is the most advanced LSD program in clinical development, by a wide margin.
Read at BioSpace / Definium Therapeutics